Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PLA2G7 | Q13093 | 5/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5777281 | 0.90 | HDAC8 (0.34) | HDAC8ALDH1A1HSD17B10KMT2ACYP3A4 | |
| SCHEMBL5777440 | 0.88 | HDAC8 (0.35) | HDAC8HDAC4PLA2G7CYP3A4 | |
| SCHEMBL5774087 | 0.85 | CNR1 (0.36) | HDAC8 | |
| SCHEMBL5775799 | 0.85 | HDAC8 (0.34) | HDAC8PLA2G7 | |
| SCHEMBL5773577 | 0.83 | NAMPT (0.35) | HDAC8HDAC4 | |
| SCHEMBL5774678 | 0.82 | MAPT (0.42) | ALDH1A1LMNAKMT2ACYP3A4CYP2D6 | |
| SCHEMBL5775533 | 0.82 | HDAC8 (0.33) | HDAC8HDAC4PLA2G7 | |
| SCHEMBL5773350 | 0.82 | TSHR (0.40) | MPOALDH1A1LMNAPLA2G7CYP3A4 | |
| SCHEMBL5773778 | 0.81 | PLA2G7 (0.36) | HDAC8ALDH1A1HDAC4HDAC2HDAC6 | |
| SCHEMBL5774849 | 0.81 | HDAC4 (0.33) | HDAC8ALDH1A1HDAC4HDAC6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | MPO 1350/4885HDAC8 639/4885ALDH1A1 1045/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | MPO 2320/4885HDAC8 569/4885ALDH1A1 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.